PhosphoDynamics AB is owned and operated by Lars Rönnstrand, PhD, professor of Molecular Medicine at Lund University. He has more than three decades of experience from working on cancer research with expertise in growth factor receptor/receptor tyrosine kinase signaling, mechanisms of oncogenic transformation, targeted inhibitors for treatment of cancer, mechanisms of resistance to targeted inhibitors, discovery of novel treatment options, mechanism of transformation of oncogenic tyrosine kinases, in vitro and in vivo model systems, generation of highly selective peptide antibodies, generation of highly selective phosphospecific antibodies, generation of other posttranslational modification selective antibodies. He has served in several evaluation committees both for positions and project grants, including the Swedish Research Council etc. He served as expert witness in the patent litigation processes between Teva and Novartis, and Apotex and Novartis regarding the patent on Gleevec in Toronto, Canada 2013. He has serves as consultant for several major pharmaceutical companies and is presently in the advisory board of OncoSignature AB and Acrivon Therapeutics.
Phone +46 768870263
E-mail: Lars.Ronnstrand@phosphodynamics.com
Websites of some of our collaborators and colleagues:
http://www.ronnstrandlab.com
http://www.ronnstrand.com
http://www.melanoma.se
http://www.leukemia.se
http://www.kazilab.se
http://www.med.lu.se